Next Article in Journal
Fentanyl and Spiradoline Interactions in a Place-Conditioning Black-White Shuttle-Box
Previous Article in Journal
Drug Induced Hypersensitivity and the HLA Complex
Previous Article in Special Issue
EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
Open AccessArticle

Molecular Therapies in Thyroid Cancer

Northwestern University, Feinberg School of Medicine, Division of Hematology/ Oncology, Department of Medicine, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2011, 4(1), 91-100; https://doi.org/10.3390/ph4010091
Received: 2 November 2010 / Revised: 9 December 2010 / Accepted: 22 December 2010 / Published: 24 December 2010
(This article belongs to the Special Issue Targeted Therapy)
Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer. View Full-Text
Keywords: advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors
MDPI and ACS Style

Huyck, T.; Agulnik, M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011, 4, 91-100.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop